SYGN 303

Drug Profile

SYGN 303

Alternative Names: SYGN-303

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synedgen
  • Class Polysaccharides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Intestinal obstruction

Most Recent Events

  • 27 Oct 2016 Pharmacodynamics data from a preclinical study in Intestinal obstruction in cystic fibrosis released by Synedgen
  • 28 Jul 2016 Preclinical trials in Intestinal obstruction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top